Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06402331 is registered in ClinicalTrials.gov with Fusion Pharmaceuticals Inc. as lead sponsor.

NCT NCT06402331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06402331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Fusion Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 5, 2024
Completion date
January 23, 2031
Enrollment
110 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer